Enhanced mammalian target of rapamycin (mTOR) signalling contributes to the pathogenesis of diabetes and plays a critical role in myocardial ischaemia/reperfusion (I/R) injury. Rapatar is a novel nanoformulated micellar of rapamycin, a putative inhibitor of mTOR that has been rationally designed to increase water solubility of rapamycin to facilitate p.o. administration and enhance bioavailability. We examined the effect of Rapatar on the metabolic status and protection against myocardial I/R injury in type 2 diabetic mice.
Introduction
Accumulating evidence from clinical and epidemiological studies indicates that the hearts of diabetic subjects are more prone to ischaemia/reperfusion (I/R) injury, which leads to a higher mortality rate compared with non-diabetics (Luo et al., 2013; Das et al., 2015a) . A chronic increase in mammalian target of rapamycin (mTOR) and its related signalling contributes to the pathogenesis of diabetes including a disrupted cellular metabolic homeostasis, insulin resistance, impaired insulin secretion, pancreatic beta-cell dysfunction and programmed cell death with apoptosis and autophagy (Khamzina et al., 2005; Ranieri et al., 2010) . mTOR is the catalytic subunit of two distinct complexes called mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). A persistent hyperactivation of mTORC1 occurs in both genetic and diet-induced animal models of obesity and metabolic disorders in multiple organs including the heart (Sciarretta et al., 2012; Yang and Ming, 2012) . In the metabolic syndrome model of spontaneously hypertensive rats, enhanced mTORC1 activation in the heart led to cardiac hypertrophy (Soesanto et al., 2009) . In diet-induced obesity and a metabolic syndrome mouse model, cardiac mTORC1 activity was increased and remained elevated during ischaemia and was associated with suppression of autophagy (Sciarretta et al., 2012) . Importantly, pretreatment of these mice with the mTOR inhibitor, rapamycin, significantly reduced ischaemic myocardial infarct size. Previous studies showed that selective pharmacological and genetic inhibition of mTORC1 extend lifespan with a reduction of pathological hypertrophy and cardiac damage after myocardial infarction and metabolic disorders (Sciarretta et al., 2014; Volkers et al., 2014) . Based on its pathophysiological importance, mTOR signalling has attracted broad scientific and clinical interest as a potential therapeutic target to treat diabetes-associated cardiovascular diseases. Our study demonstrated the beneficial effect of rapamycin in improving metabolic status and preventing cardiac dysfunction in type 2 diabetic (T2D) mice (Das et al., 2014) . Rapamycin attenuated oxidative stress, affecting the levels of antioxidant proteins and improves metabolic status by regulating metabolic proteins. Treatment with rapamycin at the onset of reperfusion after acute ischaemia also protects diabetic hearts against reperfusion injury through activation of STAT3 signalling and targeted inhibition of mTORC1 (Das et al., 2015b) .
One of the limitations of rapamycin is its poor water solubility and instability in aqueous solution. Therefore, its clinical application through p.o. administration, especially during chronic treatment, may limit its bioavailability and efficacy. Rapatar is a novel nanoformulated micelles of rapamycin (based on Pluronic block copolymers as nanocarriers) that was rationally designed to increase water solubility of rapamycin to facilitate p.o. administration and enhance bioavailability (Pietrzynski et al., 2016) . Rapatar has been shown to prevent the development of benign prostatic hyperplasia in rats (Lesovaya et al., 2015) and extended lifespan in cancer-prone mice (Comas et al., 2012) . Based on these promising studies, we examined the effect of chronic treatment of Rapatar on (i) metabolic status; (ii) regulation of mTOR complexes; (iii) cardioprotective signalling including the phosphorylation of STAT3, ERK1/2, AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3β (GSK3β); and (iv) infarct size and cardiac function following I/R injury in T2D mice.
Methods

Animals
Adult male leptin receptor null, homozygous db/db mice (strain: BKS.Cg-Dock7 m +/+ Lepr db /J) were purchased from
The Jackson Laboratory (Bar Harbor, ME, USA). The animal experimental protocols were approved by the Institutional Animal Care and Use Committee of the Virginia Commonwealth University. The experiments were conducted according to the Guide for the Care and Use of Laboratory Animals for Biomedical Research published by the National Institutes of Health (no. 85-23, revised 1996) . Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Housing and husbandry
Mice were grouped, housed in individual ventilated grommet cages (three mice per cage) at room temperature 21-23°C with a humidity of 40-60%, 12 h light/dark cycle and ad libitum access to water and chow diet. Mice were housed in specific pathogen-free zones. Cages were lined with sterilized Bed-o'Cobs bedding material and changed daily. Mice were given~14 days to acclimatize to the housing conditions before the start of the experiments.
Experimental groups and treatment protocol
Twenty-four adult male db/db mice (16-18 weeks) were treated daily for 10 weeks with Rapatar (0.75 mg·kg À1 , n = 12) or an equivalent amount of control (Pluronic block water-soluble copolymer without rapamycin, n = 12) by p.o. gavage. The dose of Rapatar was chosen based on the previous studies in mice on long-term treatment with Rapatar (Comas et al., 2012) . During the treatment period, body weight and fasting blood glucose levels were monitored weekly. We performed both glucose tolerance and insulin resistance tests and measured triglyceride and insulin levels in the db/db mice following 10 weeks of treatment with Rapatar. Upon completion of treatment, the mice were anaesthetized with pentobarbital sodium (70 mg·kg À1 i.p.), and the heart was quickly connected to a Langendorff perfusion system for global I/R or frozen in liquid nitrogen and stored at À80°C until further experiments. The experimental protocol is documented in Figure 1 .
Randomization
Animals were randomized by arbitrarily placing them into control and Rapatar treatment groups with identical age, body weight and fasting glucose level.
Measurement of plasma triglyceride and insulin
After the mice had been killed (after 4 h of fasting), blood was collected in a heparin-treated BD Vacutainer® tube and centrifuged at 1000× g for 15 min at 4°C. The clear top yellow plasma layer was stored at À80°C until analysis. The plasma triglycerides were assayed using commercially available 
Measurement of cardiac function by echocardiography
Cardiac contractile function was measured at baseline and after 10 weeks of treatment with Rapatar using the Vevo 770TM imaging system (VisualSonics, Inc., Toronto, Canada). A 30 MHz probe was used to obtain twodimensional, M-mode and Doppler imaging from parasternal short-axis view at the level of the papillary muscle and the apical four-chamber view (Salloum et al., 2008; Das et al., 2014) . Left ventricular (LV) wall thickness, LV end-systolic diameter (LVESD) and LV end-diastolic (LVEDD), fractional shortening (FS) and ejection fraction (EF) were calculated using Vevo analysis software (version 2.2.3). The experimenter was blinded to the treatment allocation.
Langendorff isolated perfused heart and ischaemia/reperfusion protocol
The methodology for the isolated perfused heart preparation has been described previously in detail (Khan et al., 2006; Das et al., 2008 Das et al., , 2009 Das et al., , 2012 . In brief, mice were anaesthetized with sodium pentobarbital (Nembutal® sodium solution; 100 mg·kg À1 i.p.). The heart was removed, and aorta was cannulated on a 20-gauge blunt needle connected to Langendorff perfusion system. The heart was perfused at a constant pressure of 55 mmHg with modified Krebs-Henseleit solution (in mM): NaCl 118, NaHCO 3 24, CaCl 2 2.5, KCl 4.7, KH 2 PO 4 1.2, MgSO 4 1.2, glucose 11 and EDTA 0.5, continuously gassed with 95% O 2 + 5% CO 2 (pH 7.34-7.49). Buffer and heart temperature were maintained at 37°C. A force-displacement transducer (Grass, Figure 1 Experimental protocol for drug treatments and major endpoints.
model FT03) was attached to the apex through a no. 5 surgical thread and a rigid metal hook. The resting tension of the isolated heart was adjusted to~0.30 g. Ventricular contractile force was recorded by Powerlab 8SP computerized data acquisition system connected to the force transducer. After 20 min of stabilization, the hearts were subjected to 30 min of noflow global ischaemia followed by 60 min of reperfusion. Coronary flow rate was calculated by timed collection of the outflow perfusate. Rate-force product was measured as the product of heart rate and ventricular developed force. After the end of reperfusion, the heart was weighed, frozen and cut into 6-8 transverse slices from apex to base of equal thickness (~1 mm). The slices were stained with 10% tetrazolium chloride for 30 min, and infarct size was determined by computer morphometry using image J software.
Blinding
The treatment groups were blinded to the operator of the Langendorff I/R protocol and echocardiography. All other data analyses were performed in a blinded fashion, except for Western blots, in order to maintain a consistent pattern of protein loading for each group.
LDH assay
Coronary effluent was collected before 5 min of ischaemia and after 10 min of beginning of reperfusion. The LDH assay was performed according to the manufacturer's protocol of the LDH-cytotoxicity assay kit (BioVision Research Product, BioVision Inc., Milpitas, CA, USA).
Western blot analysis
Total soluble protein was extracted from the whole heart tissue after completion of the experimental protocol, as described above. The extraction buffer consisted of 20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.2 mM PMSF, 1 μg·mL À1 pepstatin, 05 μg·mL À1 leupeptin, 2 mM NaF, 0.2 mM Na 3 VO 4 and 5 mM β-mecaptoethanol. The homogenate was centrifuged at 14 000× g for 15 min at 4°C, and the supernatant was recovered. Protein (50 μg) from each sample was separated by SDS-PAGE and transferred onto a nitrocellulose membrane (Das et al., 2005 (Das et al., , 2009 -GSK, GSK, Bcl-2 and Bax from Cell Signalling Technology, Danvers, MA, USA and GAPDH from Santa Cruz Biotechnology, Dallas, TX, USA). The membrane was washed and incubated with HRP-conjugated secondary antibody (1:2000 dilutions) for 1 h. The blots were developed using a chemiluminescent system (Amersham, ECL Plus; GE Healthcare Bio-Sciences, Pittsburgh, PA, USA).
Data analysis and statistics
Statistical analysis was performed with GraphPad Prism 4.0 (GraphPad Software Inc., La Jolla, CA, USA). Data are presented as mean ± SEM. Statistical comparisons between two groups were performed with the Student's unpaired t-test. P < 0.05 was considered to be statistically significant. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharma cology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b) .
Results
Effect of chronic treatment with Rapatar on metabolic status
The gain of body weight of db/db mice was significantly repressed following 10 weeks of treatment with Rapatar as compared with control db/db mice (Figure 2A ). Blood glucose level of db/db mice decreased significantly with chronic treatment with Rapatar as compared with controltreated db/db mice ( Figure 2B ). After 8 and 10 weeks of Rapatar treatment, blood glucose levels of db/db mice were significantly reduced to 17.0 ± 1.9 and 14.4 ± 1.4 mM, respectively, as compared with control db/db mice (27.6 ± 1.3 and 26.5 ± 1.1 mM, respectively) (n = 10, *P < 0.05). After 10 weeks of Rapatar treatment, a significant decrease in plasma triglyceride level in db/db mice (0.64 ± 0.07 mM) was observed as compared with the control db/db mice (1.17 ± 0.06 mM) ( Figure 2C ). Rapatar maintained a high level of plasma insulin in db/db mice (13.68 ± 2.2 ng·mL À1 ) as compared with control db/db mice (6.93 ± 1.8 ng·mL À1 ) ( Figure 2D ). However, there was no significant difference in HOMA-IR between the groups (control: 192.3 ± 38.2 vs. Rapatar: 208 ± 33.8) ( Figure 2E ). Rapatar also decreased liver and heart weight as compared with control db/db mice ( Figure 2F, G) . The blood glucose levels in db/db control mice remained elevated up to 120 min after i.p. glucose administration, which indicated glucose intolerance ( Figure 3A ). Chronic treatment with Rapatar significantly improved glucose tolerance, indicated by almost linear suppression of glucose level after 45 min of glucose administration and a significant reduction of area under the curve (AUC) as compared with db/db control mice ( Figure 3A, B) . The insulin tolerance test (ITT) assay and AUC for ITT also demonstrated the impairment of insulin sensitivity in db/db mice, which was improved following chronic Rapatar treatment ( Figure 3C, D) .
Effect of Rapatar on cardiac function
Chronic Rapatar treatment did not alter the anterior or posterior wall diastolic/systolic thickness in db/db mice ( Figure 4A , B and C, D). Although LVEDD and LVESD were reduced following chronic Rapatar treatment in db/db mice, these reductions were not significant as compared with db/db control mice ( Figure 4E, F) . However, Rapatar treatment significantly improved left ventricular FS (29.6 ± 1.9%) and EF (59.9 ± 3.1%) as compared with control-treated db/db mice (FS: 22.29 ± 1.64%, EF: 45.3 ± 2.9%) ( Figure 4G, H) . No differences in heart rate were observed between groups (control: 257 ± 23 b·min À1 and
Rapatar: 279 ± 28 b·min À1 ).
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Effect of Rapatar on ischaemia/reperfusion injury
The chronic Rapatar treatment for 10 weeks significantly reduced myocardial infarct size of db/db mice (17.04 ± 1.8%) following 30 min of global ischaemia and 60 min of reperfusion as compared with the control db/db mice (36.3 ± 0.7%) (*P < 0.05; n = 6) ( Figure 5A , B). Cardiac function (rate-force product, measured as product of heart rate and ventricular developed force) was also improved in Rapatar-treated db/db hearts following I/R as with control db/db ( Figure 5C ). However, coronary flow rate did not change between groups following I/R ( Figure 5D ). LDH level in coronary effluents collected from both control-treated and Rapatar-treated hearts following 10 min of starting of reperfusion significantly increased as compared with their respective baseline (5 min before ischaemia) ( Figure 5E ). However, significant reduction of LDH release in coronary effluent of Rapatar-treated db/db heart (295 ± 11%, n = 6) was observed as compared with control db/db heart (392 ± 16%, n = 5) following 30 min ischaemia and 10 min of reperfusion (*P < 0.05) ( Figure 5E ).
Effect of Rapatar on phosphorylation of S6, Akt and GSK3β
The phosphorylation of ribosomal protein S6 was significantly suppressed in the hearts of db/db mice following
Figure 2
Effect of chronic Rapatar treatment on (A) body weight, (B) blood glucose levels, (C) triglyceride and (D) insulin levels, (E) HOMA-IR, (F) liver weight and (G) ratio of heart weight and tibia length of db/db mice.
treatment with Rapatar, without alteration of total S6 ( Figure 6A , B, D). However, the phosphorylation of Akt (Ser 473 ) was significantly increased in Rapatar-treated group, while having no effect on total Akt ( Figure 6A , C, E). One of the downstream targets of activated Akt is GSK3β (Tong et al., 2002; Das et al., 2008) . Rapatar enhanced phosphorylation of GSK3β (Ser 9 ) in the hearts of db/db mice ( Figure 7A ).
Effect of Rapatar on Bax and Bcl-2
Chronic treatment with Rapatar enhanced the expression of Bcl-2 in the hearts of db/db mice, but no effect on the expression of the pro-apoptotic protein Bax ( Figure 7B ). Nevertheless, the ratio of Bcl-2 to Bax was increased with Rapatar treatment in the hearts of db/db mice.
Effect of Rapatar on phosphorylation of AMPK, STAT3 and MAPKs
The phosphorylation of AMPK (Thr 172 ) was significantly increased in the hearts of Rapatar-treated db/db mice ( Figure 8A ). Phosphorylation of STAT3 (Tyr 705 ) was also induced following Rapatar treatment ( Figure 8B ). Rapatar also enhanced the phosphorylation of ERK1/2, without change in p38 phosphorylation (Figure 9 ).
Discussion
Pathophysiological alterations in the diabetic heart lead to increased susceptibility to I/R injury with severe adverse consequences, including a substantial rise in the risk of death (Pfeffer et al., 2015) . Extensive research over the past two decades has established the central role of mTOR in maintaining tissue homeostasis, and inadvertent activation of mTOR is implicated in the progression of diabetes (Saxton and Sabatini, 2017) . Chronic activation of mTORC1 is causal for the pathogenesis of diabetic cardiomyopathy, and specific inhibition of mTORC1 prevents metabolic remodelling and cardiac dysfunction (Volkers et al., 2014) . Mice with high-fatdiet-induced obesity and metabolic syndrome exhibited dysregulation of mTORC1 and exacerbated myocardial injury in response to prolonged ischaemia (Sciarretta et al., 2012) . Both 
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pharmacological inhibition of mTORC1 with rapamycin and genetic ablation of mTORC1 are protective during myocardial ischaemia, suggesting that mTORC1 inhibition is a novel therapeutic strategy in diabetic heart against ischaemic injury (Sciarretta et al., 2012) . Previously, we also demonstrated that chronic treatment with rapamycin (0.25 mg·kg À1 ·day
À1
for 28 days) improves the metabolic status of diabetic mice and prevents cardiac dysfunction with attenuation of oxidative stress (Das et al., 2014) . A recent study from The Jackson Laboratory showed that 6 weeks of dietary treatment with rapamycin improved glucose metabolism, increased insulin sensitivity and decreased hyperinsulinaemia in T2D mice (Reifsnyder et al., 2016) . In contrast, a previous study with rapamycin failed to improve metabolic function in obesityinduced diabetes (Laplante and Sabatini, 2012) . Relatively high dose of chronic rapamycin treatment (~2 mg·kg À1 ·day À1 for 14 days) impairs whole-body insulin sensitivity by disrupting the integrity of mTORC2 in normal mice and rats (Houde et al., 2010; Lamming et al., 2012) . Remarkably, recent compelling studies indicate that rationally designed treatment of prediabetic animals with mild doses of rapamycin attenuated or even reversed the development of various diabetic complications, including insulin resistance, retinopathy and nephropathy (Blagosklonny, 2013; Leontieva et al., 2014) . A recent study also reported that chronic inhibition of mTORC1 by selective S6K1 inhibitor, PF-4708671, improves glucose homeostasis in obese mice through enhanced Akt activation in liver and muscle (Shum et al., 2016) . To this context, it is reasonable to assume that optimization of dosage regimen, delivery route and formulation of rapamycin may provide exclusive cardioprotective benefit by improving metabolism without inhibiting mTORC2 activity in diabetic mice. The current study utilized Rapatar, which is a novel nanoparticle-formulated rapamycin, in a murine model of type 2 diabetes. After 10 weeks of treatment, Rapatar reduced gain of body weight, liver weight, fasting blood glucose and triglyceride levels, but increased plasma insulin level, consequently improving glucose tolerance and insulin sensitivity in db/db mice. In general, db/db mice exhibit hyperinsulinaemia due to sustained mTOR activation in young mice (Fujiwara et al., 1991; Davis et al., 2010; Yuan et al., 2017) . We previously showed that hyperinsulinaemia of 16-to 18-week-old db/db mice was suppressed following 28 days of rapamycin treatment (Das et al., 2015) . However, prolonged hyperactivation of constitutive mTORC1 diminishes pancreatic beta-cell mass by inducing apoptosis and insulin deficiency, leading to progressive hyperglycaemia in the late stages of T2D (Fujiwara et al., 1991; Davis et al., 2010; Yuan et al., 2017) . Earlier studies on db/db mice indicated that elevated plasma insulin levels gradually declined in concert with progressive hyperglycaemia with the age (Arakawa Davis et al., 2010) . In the present study, we demonstrated that 10 weeks of Rapatar treatment prevented the age-related gradual decline of plasma insulin levels in 26-to 28-week-old db/db mice and enhanced insulin sensitivity that may prevent the exhaustion of pancreatic beta cells possibly through the alleviation of glucose toxicity. Furthermore, chronic Rapatar treatment attenuated diabetes-induced cardiac dysfunction in db/db mice, similar to rapamycin treatment (Das et al., 2015) . Moreover, Rapatar treatment reduced myocardial infarct size in diabetic heart following global I/R with improved post-ischaemic cardiac function and coronary flow rates.
Genetic and pharmacological evidence demonstrates that specific mTORC1 inhibition is beneficial after myocardial infarction (Buss et al., 2009; Das et al., 2012; Sciarretta et al., 2012) . However, activation of mTORC2 plays a pivotal role in cardioprotection against myocardial ischaemic injury (Volkers et al., 2013; Yano et al., 2014) . Therefore, selective activation of mTORC2 with concurrent inhibition of mTORC1 signalling may be the most pertinent therapeutic approach for the treatment of ischaemic heart disease. We previously reported that chronic treatment with rapamycin specifically inhibits phosphorylation of S6 (target of mTORC1) in hearts of db/db mice, without interfering with phosphorylation of Akt (Ser 473 , target of mTORC2) (Das et al., 2015) . Rapamycin treatment at the onset of reperfusion also reduces mTORC1 activity, but induced mTORC2 activity, which may provide cardioprotection in diabetic heart following I/R (Das et al.,
Figure 6
Effect of chronic treatment with Rapatar on phosphorylation of S6 and Akt in hearts of db/db mice. (A) Representative immunoblots of phospho-S6, total S6, phospho-Akt, total Akt and GAPDH in hearts of db/db mice following 10 weeks of treatment with Rapatar. Densitometry analysis of the ratios of (B) p-S6 to S6, (C) p-Akt to Akt, (D) S6 to GAPDH and (E) Akt to GAPDH. 2015b). In the present study, we identified that chronic treatment with Rapatar reduced the phosphorylation of S6 while increasing the phosphorylation of Akt, which may be beneficial for protection of diabetic heart against I/R injury. GSK3β regulates glycogen synthesis in response to insulin and activation of GSK3β induces myocardial apoptosis and becomes inactivated when phosphorylated at Ser 9 by activated Akt (Cohen and Frame, 2001 ). Inhibition of GSK3β attenuates myocardial I/R injury through inhibition of mitochondrial permeability transition pore opening (Hirotani et al., 2007; Zhai et al., 2011) . mTORC2 activation plays a pivotal role in cardioprotection by phosphorylation of GSK3β (Yano et al., 2014) . The current study also shows an increase in phosphorylation of GSK3β following chronic Rapatar treatment, which may lead to increase in the expression of pro-survival protein Bcl-2 as well as the ratio of Bcl-2 to Bax.
AMPK, a negative regulator of the Rheb/mTORC1 pathway, was reduced in diabetic mice both at baseline and during ischaemia, as indicated by reduction in its phosphorylation status (Sciarretta et al., 2012) . Activation of AMPK reduces myocardial infarct size in diabetic rat (Paiva et al., 2011) . Our results show that chronic treatment with Rapatar induced the phosphorylation of AMPK in hearts of db/db mice, suggesting that it may have improved cardiac function and overcome the increased susceptibility of the diabetic heart to I/R injury by phosphorylating Akt and GSK3β.
Our previous study revealed that acute treatment of rapamycin triggers the phosphorylation of ERK1/2, which may phosphorylate STAT3, without altering the
Figure 7
Effect of chronic treatment with Rapatar on phosphorylation of GSK3β, Bcl-2 and Bax levels in hearts of db/db mice. (A) Representative immunoblots of phospho-GSK3β, total GSK3β and GAPDH and the densitometry analysis of the ratio of p-GSK-3β to GSK3β as well as GSK3β to GAPDH. (B) Representative immunoblots of Bcl-2, Bax and GAPDH as well as the ratio of Bcl-2 to GAPDH, Bax to GAPDH and Bcl-2 to Bax.
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phosphorylation of p38 in myocardium of normal mice (Das et al., 2012) . Rapamycin treatment at reperfusion also increased phosphorylation of ERK, with simultaneous inhibition of phosphorylation of p38 in hearts of C57 mice (Filippone et al., 2017) . Interestingly, STAT3 signalling plays a crucial role in reducing myocardial infarction and attenuates cardiomyocytes death following reperfusion therapy with rapamycin only in the diabetic mice (Das et al., 2015b) , not in normal mice (Filippone et al., 2017) . In the present study, we observed that chronic treatment of diabetic mice with Rapatar caused significant increase in the phosphorylation of ERK1/2, as well as STAT3. Since STAT3 activation is required for initiation of Akt activation, which leads to cardioprotection by reducing myocardial infarction (Fuglesteg et al., 2008; Goodman et al., 2008) , we predict that ERK activates STAT3 and Akt and inhibits downstream target GSK3β, which may mediate Rapatar-induced cardioprotection by inducing the ratio of Bcl-2 to Bax.
In summary, our results provide evidence that chronic p.o. administration of Rapatar, nanoformulated micelles of rapamycin, improved the metabolic status and cardiac function with a reduction of infarct size following myocardial I/R injury in T2D mice. Rapatar specifically inhibited the activation of mTORC1, but activated the mTORC2, AMPK, ERK and STAT3 signalling pathway. The present study provides novel mechanistic insights into Rapatar-
Figure 8
Effect of chronic treatment with Rapatar on phosphorylation of AMPK and STAT3 in hearts of db/db mice. (A) Representative immunoblots of phospho-AMPK, total AMPK and GAPDH and the ratio of phospho-AMPK to AMPK and AMPK to GAPDH. (B) Representative immunoblots of phospho-STAT3, total STAT3 and GAPDH and the ratio of phospho-STAT3 to STAT3 and STAT3 to GAPDH. induced cardioprotection in diabetic mice, which may be a potentially safe and novel therapeutic option for diabetesinduced cardiovascular complications.
Figure 9
Effect of chronic treatment with Rapatar on phosphorylation of ERK and p38 in hearts of db/db mice. Top panel: representative immunoblots of phospho-ERK1/2, total ERK1/2, phosphor-p38, total p38 and GAPDH. Bottom panel: densitometry analysis of the ratio of phospho-ERK1 to ERK1, phospho-ERK2 to ERK2, ERK1 to GAPDH and ERK2 to GAPDH as well as phospho-p38 to p38 and p38 to GAPDH.
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